Eledon Pharmaceuticals, Inc. Common Stock

ELDNNASDAQUSD
3.41 USD
0.19 (5.28%)AT CLOSE (11:59 AM EDT)
3.49
0.08 (2.35%)
POST MARKET (AS OF 07:52 PM EDT)
Post Market
AS OF 07:52 PM EDT
3.49
0.08 (2.35%)
🔴Market: CLOSED
Open?$3.59
High?$3.60
Low?$3.38
Prev. Close?$3.60
Volume?757.8K
Avg. Volume?1.1M
VWAP?$3.45
Rel. Volume?0.68x
Bid / Ask
Bid?$3.35 × 100
Ask?$3.50 × 100
Spread?$0.15
Midpoint?$3.43
Valuation & Ratios
Market Cap?263.2M
Shares Out?77.2M
Float?52.3M
Float %?87.3%
P/E Ratio?N/A
P/B Ratio?5.88
EPS?-$0.99
Dividend?0.00%
Ex-Dividend?N/A

Shares of Eledon Pharmaceuticals, Inc. Common Stock (ELDN) are trading at $3.41. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, ELDN trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Employees
33
Market Cap
263.2M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2014-09-17
Address
19800 MACARTHUR BLVD.
IRVINE, CA 92612
Phone: 949-238-8090
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-1/3)
Medium-Term (Wave)? Bearish(-3/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
65
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.91Distress
Confidence?50%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.96%High
Short Interest?6.8M
Days to Cover?5.4
Free Float52.3M
Avg Daily Volume1.3M
Settlement Date2026-05-15
Financial Health
Current Ratio?8.44Strong
Quick Ratio?8.44Strong
Cash Ratio?0.46Low
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A
P/B?
Peers
100
S&P
31
5.88FAIR
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-3.0CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-171.0%WEAK
ROA?
S&P
3
-52.2%WEAK
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$257.1M
Fundamentals ratios updated end of day